batimastat
Batimastat is a synthetic peptidomimetic compound that functions as a broad-spectrum matrix metalloproteinase (MMP) inhibitor. It was developed by British Biotech in the early 1990s. MMPs are a family of enzymes involved in the breakdown of extracellular matrix, a process crucial for tissue remodeling, wound healing, and cell migration. However, aberrant MMP activity is also implicated in various pathological conditions, including cancer invasion and metastasis, arthritis, and cardiovascular disease.
Batimastat's mechanism of action involves binding to the active site of MMPs, thereby preventing them from
Despite initial promise and clinical trials, particularly in the treatment of solid tumors, batimastat did not